A Single Dose-escalation Study to Evaluate the Safety and Clinical Activity of Allogeneic Chimeric Antigen Receptor T Cells Targeting CD19 in Patients With Refractory or Relapsed B Cell Malignancies.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ThisCART 19 (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Suzhou Fundamenta Therapeutics

04 Jun 2024 Results (n=13) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
10 Apr 2024 Results( Cut off 01 January 2024,) assessing the safety and efficacy of CART19 in patients with B-cell malignancies presented at the 115th Annual Meeting of the American Association for Cancer Research.
17 Jun 2022 Results (n=8; as of 30 Jan 2022) of preliminary analysis reporting safety and clinical response presented at the 27th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com